目的 探讨益肾康胶囊与阿魏酸哌嗪联合治疗慢性肾小球肾炎的临床疗效。方法 选择2019年12月—2021年12月在华中科技大学同济医学院附属梨园医院诊疗的98例肾炎患者，随机分为对照组和治疗组，每组各49例。对照组口服阿魏酸哌嗪片，100～200 mg/次，1次/d。在对照组基础上，治疗组口服益肾康胶囊，2粒/次，1次/d。两组患者治疗4周。观察两组患者临床疗效，比较治疗前后两组患者症状缓解时间，尿蛋白指标24 h-尿蛋白定量（24 h-Upro）、尿微量白蛋白（mALB）和β₂-微球蛋白（β₂-MG），血清白细胞介素-1（IL-1）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）和γ干扰素（IFN-γ）水平，及不良反应情况。结果 治疗后，治疗组临床有效率为97.96%，显著高于对照组的79.59%（P＜0.05）。治疗后，治疗组症状缓解时间均早于对照组（P＜0.05）。治疗后，两组24 h-Upro、尿mALB、β₂-MG、IL-6、IL-1、TNF-α、IFN-γ水平均降低，治疗组水平低于对照组（P＜0.05）。治疗期间，治疗组不良反应率为8.16%，明显低于对照组的18.36%（P＜0.05）。结论 阿魏酸哌嗪联合益肾康胶囊治疗慢性肾小球肾炎能提高有效治疗率，并改善尿蛋白指标，降低炎性反应的水平。

Objective To investigate the clinical effect of Yishenkang Capsules combined with piperazine ferulate in treatment of chronic glomerulonephritis. Methods Patients (98 cases) with chronic glomerulonephritis in Liyuan Hospital to Tongji Medical College of Huazhong University of Science and Technology from December 2019 to December 2021 were randomly divided into control and treatment group, and each had 49 cases. Patients in the control group were po administered with Piperazine Ferulate Tablets, 100-200 mg/time, once daily. Patients in the treatment group were po administered with Yishenkang Capsules on the basis of the control group, 2 grains/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluation was evaluated, the improvement time of symptoms, the urine protein indexes 24 h-Upro, mALB and β₂-MG, the levels of IL-6, IL-1, TNF-α and IFN-γ, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 97.96%, which was significantly higher than that of the control group (79.59%, P < 0.05). After treatment, the time of symptom relief in the treatment group was earlier than that in the control group (P < 0.05). After treatment, the symptom relief time in treatment group was earlier than that in control group (P < 0.05). After treatment, the levels of 24 h-Upro, urinary mALB, β₂-MG, IL-6, IL-1, TNF-α and IFN-γ in both groups were decreased, and the levels in treatment group were lower than those in control group (P < 0.05). During the treatment, the rate of adverse reactions in the treatment group was 8.16%, which was significantly lower than 18.36% in the control group (P < 0.05). During the treatment, the adverse reaction rate in the treatment group was 8.16%, which was significantly lower than that in the control group (18.36%) (P < 0.05). Conclusion Yishenkang Capsules combined with piperazine ferulate in treatment of chronic glomerulonephritis can improve the effective treatment rate, improve the index of urinary protein and reduce the level of inflammatory reaction.

R983